Tenax Therapeutics (TENX) Capital Expenditures (2010 - 2023)
Tenax Therapeutics recorded quarterly Capital Expenditures of $1602.0 in Q2 2023, up 29.09% quarter-over-quarter from $1241.0 in Q1 2023.
Tenax Therapeutics' Capital Expenditures history runs 14 years deep, the most recent figure standing at $1602.0 for Q2 2023.
- In Q2 2023, Capital Expenditures changed N/A year-over-year to $1602.0; the TTM figure through Jun 2023 stood at -$1157.0 (down 111.93% YoY), while the FY2022 annual figure was $2323.0, down 55.77% from the prior year.
- Capital Expenditures came in at $1602.0 for Q2 2023 at Tenax Therapeutics, up from $1241.0 in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $6323.0 in Q1 2022 to a low of -$4000.0 in Q4 2022.
- A 5-year average of $1942.4 and a median of $1698.0 in 2021 frame the typical range for Capital Expenditures.
- Across the five-year window, Capital Expenditures gained 15.1% in 2019 and slumped 335.57% in 2022, its largest moves.
- Tenax Therapeutics' Capital Expenditures stood at $3574.0 in 2019, then retreated by 2.35% to $3490.0 in 2020, then sank by 51.35% to $1698.0 in 2021, then plunged by 335.57% to -$4000.0 in 2022, then soared by 140.05% to $1602.0 in 2023.
- According to Business Quant data, Capital Expenditures over the past three periods registered $1602.0, $1241.0, and -$4000.0 for Q2 2023, Q1 2023, and Q4 2022 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 133.40 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 230.60 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 21.83 Mn |
| 10 | Tenax Therapeutics | 542.72 Mn | 542.72 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 1,602.00 |
| Jun 30, 2023 | 1,602.00 |
| Mar 31, 2023 | 1,241.00 |
| Mar 31, 2023 | 1,241.00 |
| Dec 31, 2022 | -4,000.00 |
| Dec 31, 2022 | -4,000.00 |
| Mar 31, 2022 | 6,323.00 |
| Mar 31, 2022 | 6,323.00 |
| Dec 31, 2021 | 1,698.00 |
| Dec 31, 2021 | 1,698.00 |
| Sep 30, 2021 | 1,679.00 |
| Sep 30, 2021 | 1,679.00 |
| Jun 30, 2021 | 1,875.00 |
| Jun 30, 2021 | 1,875.00 |
| Dec 31, 2020 | 3,490.00 |
| Dec 31, 2020 | 3,490.00 |
| Mar 31, 2019 | 3,574.00 |
| Mar 31, 2019 | 3,574.00 |
| Dec 31, 2018 | 1,788.00 |
| Dec 31, 2018 | 1,788.00 |
| Jun 30, 2018 | 2,702.00 |
| Jun 30, 2018 | 2,702.00 |
| Mar 31, 2018 | 3,105.00 |
| Mar 31, 2018 | 3,105.00 |
| Dec 31, 2017 | 1.00 |
| Dec 31, 2017 | 1.00 |
| Sep 30, 2017 | 1,264.00 |
| Sep 30, 2017 | 1,264.00 |
| Mar 31, 2017 | 3,272.00 |
| Mar 31, 2017 | 3,272.00 |
| Mar 31, 2016 | 2,884.00 |
| Mar 31, 2016 | 2,884.00 |
| Dec 31, 2015 | 16,688.00 |
| Dec 31, 2015 | 16,688.00 |
| Sep 30, 2015 | 16,688.00 |
| Sep 30, 2015 | 16,688.00 |
| Jan 31, 2014 | 9,804.00 |
| Jan 31, 2014 | 9,804.00 |
| Apr 30, 2013 | 2,267.00 |
| Apr 30, 2013 | 2,267.00 |
| Jan 31, 2013 | 2,213.00 |
| Jan 31, 2013 | 2,213.00 |
| Jul 31, 2012 | 12,719.00 |
| Jul 31, 2012 | 12,719.00 |
| Apr 30, 2012 | 6,281.00 |
| Apr 30, 2012 | 6,281.00 |
| Jan 31, 2012 | 2,502.00 |
| Jan 31, 2012 | 2,502.00 |
| Oct 31, 2011 | 8,869.00 |
| Oct 31, 2011 | 8,869.00 |
| Apr 30, 2011 | 53,315.00 |
| Apr 30, 2011 | 53,315.00 |
| Jan 31, 2011 | 326,307.00 |
| Jan 31, 2011 | 326,307.00 |
| Oct 31, 2010 | -49,892.00 |
| Oct 31, 2010 | -49,892.00 |
| Jul 31, 2010 | -88,906.00 |
| Jul 31, 2010 | -88,906.00 |